Company Overview

Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company dedicated to investigating potential therapeutics for cancer and inflammatory dermatoses.

Recent Financial News

Date   Headline
Jun 19, 2018 PROVECTUS BIOPHARMACEUTICALS EXPANDS GLOBAL PATENT PORTFOLIO FOR ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURE
May 17, 2018 PROVECTUS BIOPHARMACEUTICALS AND PEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTICS INVESTIGATORS' CONSORTIUM (POETIC) ANNOUNCE PV-10 ABSTRACT AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
May 07, 2018 PROVECTUS BIOPHARMACEUTICALS COMPLETES ENROLLMENT OF PHASE 1B TRIAL OF PV-10 IN COMBINATION WITH KEYTRUDA® IN PATIENTS WITH METASTATIC MELANOMA
Apr 30, 2018 STUDY OF T CELL MEDIATED IMMUNITY FROM COMBINATION OF PV-10 AND IMMUNE CHECKPOINT BLOCKADE IN MURINE MELANOMA MODELS PUBLISHED IN PLOS ONE
Apr 25, 2018 PROVECTUS BIOPHARMACEUTICALS AND PEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTICS INVESTIGATORS' CONSORTIUM (POETIC) ANNOUNCE ACCEPTANCE OF PV-10 POSTER PRESENTATION AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING

Investor Contacts

Our Contact Form Mailing Address

Telephone: +1 (866) 594-5999
Fax: +1 (866) 998-0005
info@pvct.com

Provectus Biopharmaceuticals, Inc.
10025 Investment Drive, Suite 250
Knoxville, TN 37932
Investor Relations Media Relations

Provectus Biopharmaceuticals, Inc.
Email: investorrelations@pvct.com
Phone: +1 (866) 594-5999 x1

Provectus Biopharmaceuticals, Inc.
E-mail: mediarelations@pvct.com
Phone: +1 (866) 594-5999 x4
Transfer Agent

(i.e. stockholder records, transfer, change of address, etc.)
Broadridge Corporate Issuer Solutions, Inc.
P.O. Box 1342
Brentwood, NY 11717
E-mail: shareholder@broadridge.com
Telephone: +1 (877) 830-4936
Fax: +1 (215) 553-5402

Stock Performance

Today's Open 0.07
Volume 43,615
Day Range 0.07 - 0.07
52 Week Range 0.02 - 0.09
Bid/Ask 0.00 / 0.00
Bid/Ask Size 0 X 0
Previous Close 0.07
Market Cap 15.32 million
Shares Outstanding 212.83 million
Dividend/Yield 0.00 / 0.00%
EPS (TTM) -0.14
P/E Ratio (TTM) N/A

Recent XBRL Filings

Filing Date Form Type Description View
May 09, 2018 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Mar 23, 2018 10-K Annual report htmlhtml   pdfpdf   xbrlxbrl  
Nov 08, 2017 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Aug 09, 2017 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
May 10, 2017 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl